Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IFN-Gamma as a Predictor of Response to First-Line ICIs in Metastatic Melanoma
NCT07436390Completed
- Sponsor
- Institute of Oncology Ljubljana
- Start
- Mar 2024
- Primary completion
- Mar 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of pembrolizumab, nivolumab and ipilimumab in melanoma, sponsored by Institute of Oncology Ljubljana. Primary endpoint: Objective Response Rate at 28 weeks. Started Mar 2024; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT07436390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07436390.